Gemcitabine in Atypical Teratoid/Rhabdoid Tumors

Raw RNA-seq data belonging to the 'Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors' manuscript. VUMC-ATRT-03, VUMC-DIPG-10, VUMC-DIPG-11, VUMC-HGG-09, JHH-DIPG-01, HSJD-DIPG-07, and SU-pcGBM-2 neurospheres were treated with 5nM gemcitabine or DMSO as control. After 24h, cells were collected and processed as described previously. Sequencing, performed on an Illumina Nextseq 500 sequencer, data processing in the R2 platform (R2.amc.nl), and statistical analysis were also assessed as previously described.